Financial Results, Investor Meeting Schedule, Dividend Declaration, and Technical Updates - Research Reports on Quest, Abaxis, Charles River Laboratories, PerkinElmer and Covance

NEW YORK, July 30, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Quest Diagnostics Inc. (NYSE: DGX), Abaxis, Inc. (NASDAQ: ABAX), Charles River Laboratories International, Inc. (NYSE: CRL), PerkinElmer Inc. (NYSE: PKI) and Covance Inc. (NYSE: CVD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5259-100free.

--
Quest Diagnostics Inc. Research Reports
On July 24, 2014, Quest Diagnostics Inc. (Quest) reported its Q2 2014 financial results with revenues from continuing operations of $1.9 billion, up 4.8% YoY. Adjusted income from continuing operations were $157 million, or $1.08 per diluted share, compared to $164 million, or $1.06 per diluted share in Q2 2013. "Quest Diagnostics grew revenues 5% and increased EPS 2%, as we continued to make good progress executing our strategy, and as underlying trends improved for pricing and volume," said Steve Rusckowski, President and CEO of Quest. "We saw strong testing growth in infectious disease, prescription drug monitoring and general health and wellness, and launched our OncoVantage solid tumor cancer panel through an exclusive relationship with Memorial Sloan Kettering Cancer Center. We are on track to meet our commitments for 2014." The Company now anticipates full year 2014 revenue to grow 2.5% to 3.5% YoY and full year 2014 adjusted diluted EPS in the range of $4.00 to $4.10. The full research reports on Quest are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/DGX/report.pdf

--
Abaxis, Inc. Research Reports
On July 24, 2014, Abaxis, Inc. (Abaxis) reported its Q1 FY 2015 financial results (period ended June 30, 2014). The Company reported total revenues of $47.5 million, up 10.0% YoY. Income from operations totaled $7.4 million, up 60.5% YoY. Net Income increased to $4.7 million during the quarter from $3.2 million in Q1 FY 2014. Diluted EPS were $0.21, up 50.0% YoY. Clint Severson, Chairman, President and CEO of Abaxis, said, " As a result of our strategic initiatives to work more closely with our distribution partners, we were able to produce strong revenue growth for the first quarter, led by 20% growth in medical sales and a solid 8% growth in veterinary sales. We had strong unit sales of chemistry analyzers, with sales of VetScan VS2s increasing 30% and Piccolo Xpress increasing 20% during the quarter over last year's comparable quarter." The Company announced that its Board of Directors has declared a quarterly cash dividend of $0.10 per common share, payable on September 17, 2014 to shareholders of record as of the close of the business on September 3, 2014. The full research reports on Abaxis are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/ABAX/report.pdf

--
Charles River Laboratories International, Inc. Research Reports
On July 24, 2014, Charles River Laboratories International, Inc. (Charles River Laboratories) announced that it has scheduled a meeting for the investment community with its management team on August 12, 2014, Tuesday in New York. According to Charles River Laboratories, the Investors and the general public are invited to listen to a live webcast of the meeting at 8:30 a.m. EDT. The Company's management will provide an overview of its business and strategic focus. A live webcast of the meeting as well as its replay version will be accessible through the Company's website. The full research reports on Charles River Laboratories are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/CRL/report.pdf

--
PerkinElmer Inc. Research Reports
On July 24, 2014, PerkinElmer Inc. announced that its Board of Directors has declared a regular quarterly dividend in the amount of $0.07 per share of common stock . The dividend is payable on November 7, 2014, to all shareholders of record at the close of the business on October 17, 2014. The full research reports on PerkinElmer are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/PKI/report.pdf

--
Covance Inc. Research Reports
On July 25, 2014, Covance Inc. stock increased 0.27% to end the day at $86.89 compared to the previous day's closing price of $86.66. The Company's stock increased 0.58% during the past one trading month, compared to the Dow Jones Industrial Average, which rose 0.55% and compared to Standard & Poor's 500, which increased 0.96% during the same period. The full research reports on Covance are available to download free of charge at:

http://www.analystsreview.com/Jul-30-2014/CVD/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Investor-Edge